Loading...
XNAS
LSTA
Market cap17mUSD
Dec 05, Last price  
1.97USD
1D
-2.96%
1Q
-9.22%
Jan 2017
-30.39%
Name

Lisata Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:LSTA chart
P/E
—
P/S
17.38
EPS
—
Div Yield, %
—
Shrs. gr., 5y
64.65%
Rev. gr., 5y
25.25%
Revenues
1m
35,26245,724231,66483,54111,565,11869,821,29410,050,08614,329,90014,668,50017,938,79022,487,50035,283,90000000121,372,00001,000,000
Net income
-20m
L-4.10%
-1,745,039-6,051,400-10,445,473-9,242,071-25,272,517-23,305,706-47,134,469-53,769,484-38,981,244-54,872,933-80,885,952-32,656,31922,978,700-16,167,000-20,101,000-8,141,000-27,466,000-54,225,000-20,840,000-19,985,000
CFO
-19m
L-3.37%
-833,996-3,638,831-6,132,424-4,732,165-8,648,022-8,476,699-20,927,994-13,852,518-27,101,693-46,895,238-39,258,331-23,667,682-20,875,882-19,986,000-18,882,000-8,823,000-22,245,000-21,170,000-20,032,000-19,356,000
Dividend
Oct 28, 20130.0021 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
URL
https://www.lisata.com/
IPO date
Nov 03, 1995
Employees
27
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT